Cereno Scientific AB (OSTO:CRNO B) Change In Receivables : kr-2.09 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB Change In Receivables?

Cereno Scientific AB's change in receivables for the quarter that ended in Mar. 2025 was kr1.00 Mil. It means Cereno Scientific AB's Accounts Receivable declined by kr1.00 Mil from Dec. 2024 to Mar. 2025 .

Cereno Scientific AB's change in receivables for the fiscal year that ended in Dec. 2024 was kr-3.86 Mil. It means Cereno Scientific AB's Accounts Receivable increased by kr3.86 Mil from Dec. 2023 to Dec. 2024 .

Cereno Scientific AB's Accounts Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cereno Scientific AB's liquidation value for the three months ended in Mar. 2025 was kr-134.21 Mil.

Cereno Scientific AB Change In Receivables Historical Data

The historical data trend for Cereno Scientific AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Change In Receivables Chart

Cereno Scientific AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-0.20

-0.08

0.02

0.05

-3.86

Cereno Scientific AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-1.13	-1.68	-0.42	-0.99	1.00

Cereno Scientific AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.09 Mil.

Cereno Scientific AB (OSTO:CRNO B) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cereno Scientific AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cereno Scientific AB's accounts receivable are only considered to be worth 75% of book value:

Cereno Scientific AB's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	77	-	211.213	+	0.75 * 0	+	0.5 * 0
=	-134.21

Cereno Scientific AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cereno Scientific AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

4A1:Germany

Address

BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.cerenoscientific.se

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines